Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
- SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
- "We are pleased to welcome Dr. Goldberg as the 9th independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
- "Mark brings valuable clinical expertise in oncology, and his extensive biotechnology executive experience will be an asset to Anixa.
- Dr. Goldberg received his Bachelor of Arts degree from Harvard College and his medical degree from the Harvard-MIT Program in Health Sciences and Technology.